Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP000888 in Plaque and Nail Psoriasis
NCT02995473Phase 2Completed
- Sponsor
- Galderma
- Start
- Feb 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in plaque psoriasis and nail psoriasis comparing NP000888 with Vehicle (2 arms). Primary endpoints: Success rate in Investigator's Global Assessment score at 12 weeks and Percent change from baseline in total modified Nail Psoriasis Severity Index scores at 24 weeks. Started Feb 2017; status: completed.
02
Drugs
trifarotene
03
Conditions
plaque psoriasisnail psoriasis
Beyond the preview
Go deeper on NCT02995473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02995473.